At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 170 enrolled
Drug / intervention
Cyberknife plus Pembrolizumab and Trametinib +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Stereotactic Body Radiation Therapy Plus Pembrolizumab and Trametinib vs. Stereotactic Body Radiation Therapy Plus Gemcitabine for Locally Recurrent Pancreatic Cancer After Surgical Resection: an Open-label, Randomized, Controlled, Phase 2 Trial
In Brief
A Phase 2 clinical trial evaluating Cyberknife plus Pembrolizumab and Trametinib and Cyberknife plus Gemcitabine for Pancreatic Cancer. Completed, enrolled 170 participants across 1 site.
Detailed Summary
Hypothesis: Survival benefits could be found in SBRT Plus Pembrolizumab and Trametinib compared with SBRT plus gemcitabine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartOct 2016
Primary CompletionDec 2020
TodayJul 2026
First PostedMar 9, 2016
Enrollment StartOct 1, 2016
Primary CompletionDec 1, 2020
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 10.3 years ago
Interventions
Cyberknife plus Pembrolizumab and Trametinibdevice
Radiation therapy plus drug
Cyberknife plus Gemcitabinedevice
Radiation therapy plus drug